Table 1 Clinical characteristics of the study participants.
Variable | Value |
|---|---|
Age (years) | 72 (64–78) |
Sex male | 64 (55.2) |
Body mass index | 23.1 (20.8–24.9) |
Smoking status (never/ex/current) | 51/61/4 (44.0/52.6/3.4) |
Pack years | 12.8 (0–36.8) |
Underlying disease | |
IPF/IIPs other than IPF/CTD-ILD/HP/Sarcoidosis/PAP | 53/18/38/5/1/1 (45.7/15.5/32.8/4.3/0.9/0.9) |
Comorbidities | |
COPD | 17 (14.7) |
Asthma | 13 (11.2) |
Heart failure | 10 (8.6) |
Diabetes mellitus | 20 (17.2) |
Performance status (0/1/2/3/4) | 27/76/13/0/0 (23.3/65.5/11.2/0.0/0.0) |
mMRC scale (0/1/2/3/4) | 17/64/30/5/0 (14.7/55.2/25.9/4.3/0.0) |
Medication | |
Use of antifibrotic agents | 25 (21.6) |
Use of corticosteroid | 40 (34.5) |
Use of immunosuppressive drugs | 23 (19.8) |
Use of inhaled corticosteroid | 14 (12.1) |
Use of bronchodilators | 23 (19.8) |
PaO2 at rest (Torr) | 90.0 (83.8−95.1) |
FVC (% predicted) | 85.7 (74.5−100.1) |
FEV1/FVC ratio (%) | 82.1 (77.2–86.3) |
DLCO (% predicted) | 67.4 (56.7−81.4) |
GAP index (points) | 3 (2–3) |
GAP grade (I/II/III) | 94/20/2 (81.0/17.2/1.7) |
6MWT | |
Distance (m) | 420 (353−479) |
Baseline SpO2 (%) | 97 (96−98) |
Nadir SpO2 (%) | 91 (86−94) |
Heart rate, pre-test (bpm) | 80 (70−87) |
Heart rate, post-test (bpm) | 113 (99−127) |
1STST | |
Repetitions (no.) | 26 (21−30) |
Baseline SpO2 (%) | 97 (97−98) |
Nadir SpO2 (%) | 93 (88−95) |
Heart rate, pre-test (bpm) | 80 (70−87) |
Heart rate, post-test (bpm) | 108 (91−119) |
